Tim Mayleben (L) and Sheldon Koenig (Esperion)
May 17, 2021 09:10 AM EDT
People

On the heels of a sting­ing Q1 set­back, Es­pe­ri­on's long­time cham­pi­on is ex­it­ing the helm and turn­ing the wheel over to a mar­ket­ing pro

John Carroll

Editor & Founder

Just days af­ter get­ting stung by crit­i­cism from a bad­ly dis­ap­point­ed group of an­a­lysts, there’s a big change hap­pen­ing to­day at the helm of Es­pe­ri­on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Why Re­gen­eron is buy­ing 23andMe

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times